Pharma Stock Hits 5% Upper Circuit After Board Approves SME-to-Main Board Migration

Synopsis: Pharma stock hit a 5% upper circuit after approving migration from BSE SME to BSE Main Board and filing for NSE Main Board listing, and has initiated a postal ballot to seek consent.

The shares of the Micro-Cap company specializing in integrated pharmaceutical and specialty chemical manufacturing, contract research, and global product sourcing, are in focus following the strategic BSE Main Board Migration and  NSE Listing Plan.

With a market capitalization of Rs. 822.81 Crores on the day’s trade, the shares of Sudarshan Pharma Industries Ltd hit a 5 percent upper circuit, reaching a high of Rs. 34.19 compared to its previous close of Rs. 32.57.

What Happened

Sudarshan Pharma Industries, engaged in integrated pharmaceutical and specialty chemical manufacturing, contract research, and global product sourcing, has approved a key strategic move to shift its listing from the BSE SME Platform to the Main Board of BSE, subject to shareholder approval.

This step is aimed at improving visibility, liquidity, and investor participation in the stock. The company has also approved filing for listing on the Main Board of the National Stock Exchange (NSE), along with initiating a postal ballot process to seek shareholder consent for the migration.

How do they benefit from this?

Sudarshan Pharma Industries’ move from the BSE SME platform to the Main Board is expected to improve liquidity and trading activity in the stock. It will allow a larger pool of institutional and retail investors to participate, leading to better price discovery and stronger market visibility.

The migration can also enhance the company’s credibility in the capital markets, which may support higher valuation multiples over time. Additionally, a Main Board listing typically makes it easier to raise funds in the future for expansion, acquisitions, and working capital needs.

Financials & Others

The company’s revenue rose by 36.72 percent from Rs. 162 crores in March 2025 to Rs. 221 crores in March 2026. Meanwhile, Net profit rose from Rs. 7 crores to Rs. 11 crores in the same period.

The company has reported a ROCE of 15.1% and ROE of 16.3%, indicating efficient capital utilization and decent returns generated for shareholders. It also has a PEG ratio of 0.74, suggesting the stock may be reasonably valued relative to its earnings growth.

Over the longer term, the company has delivered a strong profit CAGR of 54.2% over the last 5 years, reflecting robust earnings expansion. Its working capital efficiency has also improved significantly, with the cycle reducing from 43.0 days to 17.1 days, indicating better cash flow management.

Sudarshan Pharma Industries Limited is an Indian pharmaceutical company engaged in the manufacturing, trading, and distribution of pharmaceutical products, active pharmaceutical ingredients (APIs), and intermediates.

The company offers a diversified portfolio spanning rock chemicals, intermediates, APIs, finished formulations, and fully integrated pharmaceutical and chemical solutions. Its capabilities cover the entire value chain from raw materials to advanced specialty products.

Its key clients in pharmaceutical formulations and specialty chemicals include Intas Pharmaceuticals, Minova, Invision Life Sciences, Omkar Pharma, SRF Limited, Astral Pipes, DuPont, Reliance Industries, Bayer AG, and AkzoNobel, among others.

The company has established a strong global footprint, operating across both Indian and international markets. Its presence reflects a diversified export strategy supported by consistent overseas demand. Its products are exported to several key regions, including the UK, Australia, Uzbekistan, Syria, Oman, Taiwan, and broader MENA markets, highlighting its expanding international reach and growing global acceptance.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Hits 5% Upper Circuit After Board Approves SME-to-Main Board Migration appeared first on Trade Brains.